Australia

The Therapeutic Goods Administration (TGA) is Australia's national regulatory authority responsible for the oversight of therapeutic goods, including prescription and non-prescription medicines, medical devices, biologicals, and in vitro diagnostics. The primary governing legislation is the Therapeutic Goods Act 1989 (Cth), supported by the Therapeutic Goods Regulations 1990 and a suite of product-specific orders and standards. All therapeutic goods intended for supply in Australia must be either listed or registered on the Australian Register of Therapeutic Goods (ARTG), with the pathway determined by the risk profile of the product. The TGA employs several application routes including standard applications, priority review for products addressing serious or life-threatening conditions, the provisional approval pathway for early conditional access, and the TGA Orphan Drug program for rare disease therapies. Medical devices are classified according to a risk-based framework aligned with international principles, and must meet applicable Essential Principles before inclusion in the ARTG.

Applicants must appoint an Australian sponsor, a locally registered legal entity responsible for the product's compliance and post-market obligations, before submitting to the TGA. Australia accepts dossiers prepared in the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for medicines, and applies the Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) frameworks for medical devices. The TGA participates in the Access Consortium (formerly ACSS), a collaborative review initiative with Canada, Singapore, Switzerland, and the United Kingdom, enabling parallel scientific assessment to reduce duplication. Recent reforms of significance include the introduction of the TGA International Recognition Procedure, allowing expedited registration of products already approved by comparable overseas regulators such as the European Medicines Agency, FDA, Health Canada, and Medsafe New Zealand, as well as ongoing updates to the regulatory framework for software as a medical device (SaMD) and in vitro diagnostics under the new IVD regulatory framework that took full effect in 2010 with continued refinements thereafter.

Australia's public healthcare procurement operates within a federated structure involving both the Commonwealth Government and the eight state and territory governments. At the federal level, the Pharmaceutical Benefits Scheme (PBS), administered by the Department of Health and Aged Care, is the primary mechanism for government-subsidised access to prescription medicines. Medicines must receive a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) before the government can negotiate price and list the product on the PBS formulary. For medical devices, prostheses, and certain implantable technologies used in the private hospital setting, the Prostheses List (PL) administered by the Department is the key access pathway, subject to Prostheses List Advisory Committee (PLAC) evaluation. In the public hospital sector, procurement is largely decentralised, with each state and territory health department managing its own hospital formulary, tender processes, and supply contracts through bodies such as NSW Health Procurement, Health Purchasing Victoria (HPV), and Queensland Health Procurement. National coordination frameworks, including collaborative contracts through the National Health Reform Agreement and category-level agreements facilitated by the Australian Digital Health Agency for digital health products, provide some alignment across jurisdictions.

The private sector plays a substantial role in Australian healthcare, with private hospitals, pathology providers, imaging networks, and retail pharmacy chains representing significant commercial procurement channels. Private health insurers interact with the Prostheses List to determine device benefit coverage for their members, creating a parallel commercial negotiation environment alongside public procurement. Australia is a high-income country and does not typically receive procurement support from multilateral donor agencies such as UNICEF Supply Division, the Global Fund, Gavi, or USAID; procurement is funded domestically through federal and state budgets and private insurance. However, Australian entities such as the Australian Centre for Disease Preparedness and the Department of Foreign Affairs and Trade (DFAT) participate in regional procurement and supply chain initiatives across the Indo-Pacific. There is no formal mandatory local manufacturing preference policy in standard procurement processes, though the COVID-19 pandemic accelerated policy interest in sovereign manufacturing capability, leading to targeted government investment in onshore vaccine and biologics production, including support for the Australian mRNA Vaccine Collaboration and related sovereign capability initiatives.